Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06147830 · ClinicalTrials.gov registry record
A Study to Describe the Characteristics, Health Care Interventions and Outcomes of Patients With Major Bleedings in the Presence of Factor Xa Inhibitor Treatment
A clinical trial, sponsored by AstraZeneca.
- Completed
- Registry status
- 2,202
- Enrollment target
NCT06147830 is a clinical trial that has completed, run by AstraZeneca. The registered enrollment target is 2,202 participants.
The verdict
NCT06147830 has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- 2,202 participants
- Enrollment target
Study Summary
REVERXaL study aims to increase the understanding of the patient characteristics, bleeding presentation, health care interventions provided, and the clinical as well as self-reported health outcomes of patients with major bleeding in the presence of Factor Xa inhibitor treatment. The generation of insight on treatment approaches and associated outcomes in hospitalized patients with Factor Xa inhibitor-related major bleeds may inform clinical guidelines, health system decision making and streamline treatment pathways in this population.
Interventions
- OTHER None (Observational study)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,202 participants |
| Start Date | 2023-12-04 |
| Est. Completion | 2024-11-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06147830
The ClinicalTrials.gov registry entry for NCT06147830 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 2,202 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which None (Observational study) is the first listed.
NCT06147830 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06147830 about?
NCT06147830 is a clinical study titled "A Study to Describe the Characteristics, Health Care Interventions and Outcomes of Patients With Major Bleedings in the Presence of Factor Xa Inhibitor Treatment". REVERXaL study aims to increase the understanding of the patient characteristics, bleeding presentation, health care interventions provided, and the clinical as well as self-reported health outcomes of patients with major bleeding in the presence of Factor Xa inhibitor treatment. The generation of i...
What is the current status of trial NCT06147830?
This trial is currently completed. The enrollment target is 2,202 participants. The study started on 2023-12-04. Estimated completion is 2024-11-30.
What interventions are being tested in trial NCT06147830?
The interventions under investigation include: None (Observational study) (OTHER).
Who is sponsoring clinical trial NCT06147830?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.